Skip to main content
CTOS 2025 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Bone Tumors and Orthopedics

(P 98) PERCUTANEOUS STABILIZATION OF METASTATIC BONE LESIONS WITH A PHOTODYNAMIC INTRAMEDULLARY SYSTEM: EXPERIENCE FROM A 15-PATIENT CASE SERIES

    Author(s)

  • Nikola Susic, B.S.

    Medical Student
    University of Miami Miller School of Medicine
    Coral Gables, Florida, United States

    • Co-Author(s)

  • LT

    Levi Travis, B.S.

    Medical Student
    University of Miami Miller School of Medicine, Department of Orthopaedic Surgery
    Miami, Florida, United States

  • Santiago A. Lozano Calderon, MD, PhD (he/him/his)

    Associate Professor of Orthopaedic Surgery
    Massachusetts General Hospital Department of Orthopaedic Surgery
    Boston, Massachusetts, United States

  • BC

    Brooke Crawford, MD

    Department of Orthopaedics, University of Miami
    Miami, Florida, United States

Objective: Metastatic bone lesions are a common complication of advanced malignancy, often leading to fractures, pain, and impaired mobility. Conventional fixation methods, such as intramedullary nailing and endoprosthetic reconstruction, are invasive and may delay systemic therapy. The IlluminOss® Photodynamic Bone Stabilization System is a minimally invasive alternative that may facilitate earlier recovery. This single-center case series describes our institution’s experience using IlluminOss® for stabilization of metastatic bone lesions.

Methods: With Institutional Review Board approval, records of patients with metastatic bone lesions who underwent fixation with IlluminOss® (2023–2024) were retrospectively reviewed. Demographic, clinical, surgical, and patient-reported (PR) data were collected. PR data and clinical outcomes were analyzed with mixed linear model regression and ordinal logistic mixed regression.

Results: Fifteen patients (mean age 66.87 ± 8.65 years) underwent pelvic fixation with IlluminOss®. The average BMI was 27.41 ± 6.60 kg/m², ASA classification was 3 [3–3], and 53.3% of patients were active smokers. The mean operative time was 215.20 ± 144.86 minutes, with an average blood loss of 426.31 ± 776.91 mL. The average length of stay was 9.71 ± 9.30 days, and no postoperative complications were reported. VAS pain scores significantly decreased from baseline at all follow-up time points (p < 0.05): −21.66 at 2 days, −20.85 at 2 weeks, −20.53 at 6 weeks, −30.91 at 3 months, −38.14 at 6 months, and −30.94 at 1 year. Weight-bearing status showed a significant linear increase over time (β = 2.41, p = 0.012), progressing from 0% full weight-bearing preoperatively to 93% at 1 year. Assistive device use decreased from 80% to 33% at 1-year follow-up (p = 0.017).

Conclusion: IlluminOss® fixation for metastatic pelvic lesions was safe, well-tolerated, and associated with significant pain relief, early weight-bearing, and reduced reliance on assistive devices. Further research is needed to evaluate its comparative effectiveness, long-term outcomes, and integration into multidisciplinary oncologic care pathways.